Genmab A/S Investors Should Focus on This

By Kim Brooks • Wednesday, October 16 10:11 • Permanent Link

More and more people are talking about Genmab A/S over the last few weeks. Is it worth buying the Pharmaceutical stock at a price of $22.79? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Genmab A/S has moved -21.1% over the last year, and the S&P 500 logged a change of 34.8%
GMAB has an average analyst rating of buy and is -42.17% away from its mean target price of $39.4 per share
Its trailing earnings per share (EPS) is $1.24
Genmab A/S has a trailing 12 month Price to Earnings (P/E) ratio of 18.4 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $1.64 and its forward P/E ratio is 13.9
The company has a Price to Book (P/B) ratio of 0.05 in contrast to the S&P 500's average ratio of 4.74
Genmab A/S is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53
GMAB has reported YOY quarterly earnings growth of 7.0% and gross profit margins of 1.0%
The company has a free cash flow of $5.59 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.